Claims for Patent: 9,616,114

Summary for Patent: 9,616,114

Title:	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
Abstract:	Bacterial strains are provided having at least one of a reduced size, a sialic acid coat, inducibly altered surface antigens, and expression of PD-L1 or CTLA-4 agonists and/or tryptophanase. The bacteria may have improved serum half-life, increased penetration into tumors, increased tumor targeting and increased antitumor activity. The bacteria are useful for delivery of therapeutic agents that treat of neoplastic diseases including solid tumors and lymphomas.
Inventor(s):	Bermudes; David Gordon (Woodland Hills, CA)
Assignee:
Application Number:	14/858,810
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,616,114
Patent Claims:	1. A live genetically engineered Salmonella bacterium, comprising: at least one first gene, producing at least one secreted first gene product comprising a sialic acid O-acyl transferase under control of at least one heterologous first inducible promoter; and at least one second gene, producing a secreted functional antitumor enzyme gene product under control of a second heterologous inducible promoter, the at least one first gene being distinct from the at least one second gene, the at least one heterologous first inducible promoter being distinct from the at least one heterologous second inducible promoter; the live genetically engineered Salmonella bacterium being adapted for: administration to a human or animal and colonization of at least one tissue under non-lethal conditions, after colonization of the at least one tissue, secretion of the sialic acid O-acyl transferase under control of the first inducible promoter, for action on external components of the live genetically engineered Salmonella bacterium, and after colonization of the at least one tissue, secretion of the secreted functional antitumor enzyme gene product under control of the second inducible promoter, for action against tumor cells. 2. The live genetically engineered Salmonella bacterium according to claim 1, wherein the at least one first gene further produces O-antigen transferase. 3. The live genetically engineered Salmonella bacterium according to claim 1, wherein the secreted the functional antitumor gene product comprises tyrosinase which is secreted from the live genetically engineered Salmonella bacterium in active form. 4. The live genetically engineered Salmonella bacterium according to claim 1, wherein the secreted the functional antitumor gene product comprises an amino-acid degrading enzyme which is secreted from the live genetically engineered Salmonella bacterium in active form and has anti-tumor activity against human or animal tumors colonized by the live genetically engineered Salmonella bacterium. 5. The live genetically engineered Salmonella bacterium according to claim 1, wherein the secreted the functional antitumor gene product comprises at least one enzyme selected from the group consisting of tryptophanase and asparaginase, which is secreted from the live genetically engineered Salmonella bacterium in active form. 6. The live genetically engineered Salmonella bacterium according to claim 1, wherein the first inducible promoter comprises MarA, which is induced by presence of acetyl salicylic acid. 7. The live genetically engineered Salmonella bacterium according to claim 1, wherein the first inducible promoter is responsive to at least one of tet, arabinose, hypoxia, a cellular SOS response promoter, X-rays, and mitomycin. 8. The live genetically engineered Salmonella bacterium according to claim 1, wherein the at least first gene product comprises a plurality of inducible gene products having respectively different first inducible promoters. 9. The live genetically engineered Salmonella bacterium according to claim 1, wherein the at least one heterologous first inducible promoter comprises a plurality of different heterologous inducible promoters, having respectively different pharmacological inducers which are not naturally found in human tissue, effective to promote a plurality of different ones of the at least one first gene. 10. The live genetically engineered Salmonella bacterium according to claim 1, wherein the at least one first gene comprises a plurality of first genes producing a plurality of respectively different secreted first gene products, under control of a plurality of respective different heterologous first inducible promoters, induced by respectively different pharmacological inducer agents not naturally found in humans, to thereby provide the live genetically engineered Salmonella bacterium having a plurality of different surface antigen patterns under control of a selective presence of the different pharmacological inducer agents. 11. The live genetically engineered Salmonella bacterium according to claim 1, wherein the live genetically engineered Salmonella bacterium has a selective tropism for at least one type of tumor in a human or animal, and the secreted functional antitumor enzyme gene product is effective for treating the at least one type of tumor, the live genetically engineered Salmonella bacterium being provided within a pharmaceutically acceptable formulation for administration to the human or animal. 12. The live genetically engineered Salmonella bacterium according to claim 1, wherein the live genetically engineered Salmonella bacterium is provided in a pharmaceutically acceptable formulation suitable for administration to a human or animal, and the at least one secreted first gene product is effective for increasing a serum half-life of the live genetically engineered Salmonella bacterium after administration to the human or animal in the pharmaceutically acceptable formulation as compared to the live genetically engineered Salmonella bacterium without the at least one secreted first gene product. 13. The live genetically engineered Salmonella bacterium according to claim 1, wherein the at least one heterologous first inducible promoter comprises a single promoter effective to promote a plurality of first genes to produce a plurality of respectively different secreted first gene products. 14. The live genetically engineered Salmonella bacterium according to claim 1, wherein the at least one heterologous first inducible promoter comprises a regulon comprising a mar promoter/operator region, a MarR negative regulator, a MarA positive regulator, upstream of a start codon, for promoting expression of an rfb cluster. 15. The live genetically engineered Salmonella bacterium according to claim 1, further comprising at least one third heterologous gene producing a secreted heterologous protease inhibitor. 16. The live genetically engineered Salmonella bacterium according to claim 1, having a maximum size of about 650 nm. 17. The live genetically engineered Salmonella bacterium according to claim 1, having a width of less than 401 nm. 18. The live genetically engineered Salmonella bacterium according to claim 1, wherein the at least one first gene product further comprises Lic3A, lic3B and sigA. 19. The live genetically engineered Salmonella bacterium according to claim 2, wherein the at least one first gene product is effective for producing a plurality of different 0 antigens. 20. The live genetically engineered Salmonella bacterium according to claim 1, selected to have higher CO.sub.2 resistance than wild type Salmonella.

Details for Patent 9,616,114

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2034-09-18